Monthly Archives: February 2017

About HEPLISAVHEPLISAV is an investigational adult hepatitis B vaccine.

In a completed Phase 3 trial HEPLISAV demonstrated increased, rapid protection with fewer doses than current licensed vaccines. Dynavax has worldwide commercial rights to HEPLISAV and developing the vaccine for large, high-quality less less to current licensed vaccines, including individuals with chronic kidney disease. Because.epatitis B surface antigen with a proprietary known Toll-like receptor 9 agonist ISS to enhance the immune response.. About HEPLISAVHEPLISAV is an investigational adult hepatitis B vaccine.

We believe of patients who of patients who take these drugs for a long time, they do not have heart attacks, and from heart disease from heart disease. It is our experience with this group of patients. Continue reading

Patients with impaired renal function also suffer more frequently from cardiovascular disease.

Patients with impaired renal function also suffer more frequently from cardiovascular disease. Coronary intervention in these patients are often complex and require high doses of contrast agents. Much strain on the heart and kidneys CIN is an independent mortality risk factor in these patients and a significant risk factor for cardiovascular disease, says Dr. Rainer Wessely, Associate Professor of Cardiology at the Technical University of Munich.

Hyperosmolar In this light, the investigated CONTRAST study patients with very advanced age and with severe coronary heart disease, whether the iso-osmolar contrast agent iodixanol has a better renal tolerance in this constellation over the contrast medium iomeprol. The patients whose renal function was already compromised were higher than normal quantities of contrast medium of about 360 ml on average during percutaneous coronary intervention , to the complexity of the procedures. Continue reading

Not all Democrats sold Rep.

‘. Not all Democrats sold Rep. Joe Donnelly (D-Ind. Were a member of the conservative Blue Dog Coalition and opponents of the public plan, he was not sure whether Obama is proposing a new account or easy. The case for legislation already under development in Congress ‘(Newmyer.

– There was little criticism of the president’s speech , which seemed to be universally praised by Democrats for his passion, timeliness and message, but it was also a confirmation, especially with regard to the public option debate that Obama once more went walked the line. Other staunch supporters of the public option came away satisfied, even though Obama said he was open to ideas that supporters generally considered unacceptable, such as health cooperatives and systems in which the government run plan a fall – back option (Allen, Soraghan and Rushing, this year, Roll Call reports: Moderate Democrats expressed some wariness about Obama’s push for a public insurance option, though he by it clear that he is open to other approaches paid his case, despite these hedges looking for liberals who in the talk went for a strong statement in favor of the public plan said they came away satisfied. Continue reading